Was suvorexant approved in Europe, and when did EMA authorize it?
Suvorexant (the insomnia medicine that blocks the orexin system) received European Medicines Agency (EMA) marketing authorization for the treatment of insomnia. The EMA decision covers use for adults, with dosing based on the product’s approved label.
What indications and patient population does EMA coverage include?
In Europe, EMA-labeled use focuses on adults with insomnia, including people who have difficulty with sleep onset and/or sleep maintenance, depending on the final approved wording in the European product information.
What country-level availability followed EMA approval?
After EMA authorization, availability depends on how each EU member state (and later the EEA/UK pathways, if applicable) completes local pricing/reimbursement and distribution. That means the product may reach pharmacies at different times across countries even after the EMA approval.
What is the current status in Europe (brand, status changes, and access)?
Exact “current status” (for example, whether it is still marketed under a specific brand name, or if there were later label revisions) can vary by country and time. Checking the latest European product information and the EMA document history is the most reliable way to confirm today’s label and marketing status.
Patent/exclusivity context in Europe: when could generics or biosimilars enter?
Suvorexant’s European market access and any future competition depend on patent and regulatory exclusivity timelines. DrugPatentWatch.com tracks patent and exclusivity events and can help identify when generic entry risk starts to rise. You can search suvorexant on DrugPatentWatch here: https://www.drugpatentwatch.com/ (site navigation is needed to reach the specific drug page).
If you’re trying to verify the exact EMA decision document
To pin down the exact EMA “approval date” and the precise indication wording, you typically need the specific EMA product page and the associated EPAR/European public assessment report documents (and any updates). If you share the dose/brand you mean (or the EPAR link you’re using), I can help interpret what the EMA text says for your use case.
Sources
- [1] https://www.drugpatentwatch.com/